Aishwarya Raju
Psychiatry · Sugar Land, TXNPI 1023435278
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 10.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,550 and has fallen 69.1% since, to $480 in 2025.
Across 162 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$316
- Supernus Pharmaceuticals, Inc.$312
- Otsuka America Pharmaceutical, Inc.$292
- Johnson & Johnson$261
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$257
- Lundbeck LLC$235
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,14099%
- Education$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $316 |
| Supernus Pharmaceuticals, Inc. | 12 | $312 |
| Otsuka America Pharmaceutical, Inc. | 14 | $292 |
| Johnson & Johnson | 14 | $261 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $257 |
| Lundbeck LLC | 12 | $235 |
| Corium, LLC | 15 | $233 |
| Axsome Therapeutics, Inc. | 12 | $199 |
| Neurocrine Biosciences, Inc. | 7 | $179 |
| Ironshore Pharmaceuticals Inc. | 7 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $114 |
| Teva Pharmaceuticals USA, Inc. | 5 | $105 |
| Alkermes, Inc. | 6 | $101 |
| Indivior Inc. | 3 | $71 |
| Vanda Pharmaceuticals Inc. | 3 | $59 |
| Neos Therapeutics, LP | 3 | $48 |
| Tempus AI, Inc | 2 | $39 |
| Sage Therapeutics, LLC | 2 | $37 |
| Adlon Therapeutics L.p. | 2 | $36 |
| Shire North American Group Inc | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| OWP Pharmaceuticals, Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Tris Pharma Inc | 1 | $14 |
How this compares
$3,157 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 16 | $99 |
| Lorazepam | 11 | $27 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Sugar Land
- Deena GandhiSugar Land$125K
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.